World Menopause Day 2026: A Turning Point for Women's Health
Celebrating Progress, Raising Awareness, and Closing the Menopause Care Gap
October 18, 2026 | Optimal Health and Vitality
For decades, menopause was discussed in hushed tones—if it was discussed at all. Women were often expected to quietly endure hot flashes, night sweats, sleep disturbances, mood changes, and other symptoms that could significantly affect their quality of life.
Thankfully, the conversation is changing.
Women are speaking up, asking questions, demanding answers, and advocating for better healthcare. And they deserve nothing less than access to knowledgeable clinicians, accurate information, and effective, evidence-based treatments.
Perhaps most encouraging is that the medical community, lawmakers, and federal agencies are beginning to listen.
As we celebrate World Menopause Day today on October 18, 2026, I want to highlight several important events that took place during September's Perimenopause Awareness Month and October's Menopause Awareness Month. Together, these developments represent meaningful progress toward improving the way we recognize, understand, and treat perimenopause and menopause.
September 16, 2026: Congress Takes Notice of the Menopause Care Gap
In a significant moment for women's health advocacy, a bipartisan congressional hearing titled "Half the Country, Zero Hearings: Meeting the Moment to End the Menopause Care Gap in America" brought national attention to the challenges millions of women face during menopause.
The hearing's title highlighted a remarkable reality: despite menopause affecting approximately half the population, it had never previously been the sole focus of a congressional hearing.
The discussion brought several critical issues to light.
The economic impact of untreated menopause symptoms
Menopause is not simply a personal health issue. It can also have significant professional and economic consequences.
Research from Mayo Clinic estimates that menopause-related symptoms cost American women and employers approximately $1.8 billion annually in lost work time, with the total economic burden reaching an estimated $26.6 billion when medical costs are included.
Women experiencing severe symptoms may reduce their working hours, decline career opportunities, or leave the workforce altogether.
The lack of adequate medical education
Another concerning issue discussed was the gap in menopause education among healthcare professionals.
Despite the prevalence of menopause symptoms, many clinicians receive limited formal training in recognizing and managing them. Reports suggest that approximately 80% of OB-GYN residents feel inadequately prepared to provide comprehensive menopause care.
Women deserve better.
Menopause care should not be an afterthought in medical education. It should be a fundamental component of women's healthcare.
September 17, 2026: The FDA Examines Testosterone Use in Menopausal Women
One of the most meaningful experiences for me this year was personally attending the U.S. Food and Drug Administration's public workshop, "Testosterone Use in Menopausal Women."
As a nurse practitioner specializing in perimenopause and menopause care, I was excited to participate in this important national conversation.
Testosterone is often viewed primarily as a male hormone, but it also plays important physiological roles in women's health.
Despite growing interest in testosterone therapy for women, significant research and regulatory gaps remain.
There are currently no FDA-approved testosterone products specifically formulated for women in the United States.
Consequently, clinicians who prescribe testosterone for appropriately selected female patients must rely on off-label use of products approved for men or compounded formulations.
The FDA workshop brought together experts to examine several important topics:
The existing evidence supporting testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women.
Challenges in accurately measuring testosterone concentrations in women.
The need for female-specific testosterone formulations and dosing.
Important unanswered questions regarding long-term cardiovascular and breast safety.
Opportunities for future research into testosterone's potential effects on mood, cognition, bone health, and muscle mass.
Currently, the strongest evidence supporting systemic testosterone therapy in women is for the treatment of HSDD in appropriately evaluated postmenopausal women. Although other potential benefits are being investigated, the evidence is not sufficient to recommend testosterone therapy for improving cognition, mood, bone density, or muscle mass.
Attending this workshop reinforced my belief that women deserve the same level of scientific attention, pharmaceutical innovation, and individualized treatment options that have long been available in other areas of medicine.
Women's hormonal health deserves rigorous research, thoughtful clinical care, and treatment options developed specifically for women.
The FDA also opened a public comment docket, FDA-2026-N-5479, accepting comments through October 19, 2026.
September 22, 2026: Advocating for Menopause Care on Capitol Hill
Momentum continued with Perimenopause & Menopause Capitol Hill Day, an event dedicated to raising awareness and advancing menopause-related healthcare policy.
The day included a congressional briefing followed by meetings with congressional offices to educate lawmakers about the challenges women face and advocate for the Menopause Policy Imperative.
These discussions emphasized the need for better clinical education, expanded access to evidence-based treatment, increased research funding, and policies that recognize menopause as an important public health issue.
Meaningful change requires more than awareness. It requires action from healthcare professionals, researchers, policymakers, and the women whose lives are directly affected.
September 25, 2026: Advancing Clinical Education at the Perimenopause Symposium
I also had the privilege of attending the Perry Academy's first 2026 Perimenopause Symposium in Baltimore, Maryland, on September 25.
This groundbreaking event was described by its organizers as the world's first multidisciplinary continuing education symposium dedicated entirely to perimenopause.
More than 200 clinicians representing over 10 medical specialties gathered for a full day of evidence-based education, meaningful clinical discussions, and collaborative learning.
Why is this so important?
Perimenopause can begin years before a woman's final menstrual period, and its symptoms often extend far beyond irregular menstrual cycles and hot flashes.
Women may experience changes in sleep, mood, cognition, sexual health, musculoskeletal symptoms, and metabolic health.
Because these symptoms can involve multiple body systems, women frequently seek care from different specialists without anyone connecting the dots.
The symposium reinforced the importance of a multidisciplinary, individualized approach to perimenopause care—one that considers the whole woman rather than treating each symptom in isolation.
For me, continuing education is not simply a professional requirement. It is an essential part of providing the most current, evidence-based care to the women who trust me with their health.
I left the symposium encouraged by the growing number of clinicians committed to changing the standard of care.
October 15, 2026: Updated ACOG Guidance Reflects Progress in Menopause Treatment
Another important development came on October 15, when the American College of Obstetricians and Gynecologists (ACOG) issued updated clinical guidance addressing the management of menopause symptoms.
The new guidance represents a substantial update to recommendations dating back to 2014.
It addresses multiple approaches to managing menopause-related symptoms, including:
Menopausal hormone therapy (MHT).
Nonhormonal prescription medications.
Nonpharmacologic treatment strategies.
Management of vasomotor symptoms, including hot flashes and night sweats.
Sleep disturbances and mood symptoms associated with the menopause transition.
Updated clinical guidance is especially valuable because menopause treatment is not one-size-fits-all.
For many women with bothersome vasomotor symptoms, hormone therapy can be an effective treatment when prescribed after an individualized assessment of benefits, risks, and medical history.
For others, evidence-based nonhormonal options may be more appropriate.
The goal is not to prescribe the same treatment to every woman. It is to ensure that women understand their options and can make informed decisions about their health.
October 18, 2026: World Menopause Day — Chronic Pain at Midlife
This year's World Menopause Day theme, "Chronic Pain at Midlife," brings attention to another frequently overlooked aspect of women's health.
Although hot flashes and night sweats are widely recognized symptoms of menopause, many women also experience joint discomfort, muscle pain, and changes in musculoskeletal health during midlife.
Pain can affect sleep, physical activity, emotional well-being, and overall quality of life.
Hormonal changes may contribute to some of these experiences, but not all pain during midlife is caused by menopause. Persistent symptoms deserve a thoughtful evaluation to identify other potential causes and appropriate treatment options.
The theme highlights the importance of improved research, earlier recognition, and multidisciplinary care for women experiencing pain during and after the menopause transition.
Women should never be told that significant pain or a declining quality of life is simply something they must accept as part of getting older.
The Future of Menopause Care: Awareness Must Lead to Action
Reflecting on these events, I am encouraged by the progress we are witnessing.
In just a matter of weeks, menopause has received attention from Congress, the FDA, leading medical organizations, researchers, and clinicians representing multiple specialties.
These conversations are long overdue.
But awareness alone is not enough.
We need continued investment in women's health research, better menopause education for healthcare professionals, improved access to evidence-based treatments, and a healthcare system that takes women's symptoms seriously.
Most importantly, we need to continue listening to women.
Every woman deserves to feel heard, informed, and empowered to make decisions about her health.
Our Commitment at Optimal Health and Vitality
At Optimal Health and Vitality, located in Prince Frederick, Maryland, our mission is to help women navigate perimenopause and menopause with confidence through personalized, evidence-based care.
Our approach goes beyond simply managing hot flashes. We consider the many ways hormonal changes can affect sleep, mood, sexual health, metabolic health, physical well-being, and quality of life.
Through individualized hormone therapy when appropriate, lifestyle interventions, nutrition, exercise, and proactive health optimization, we work with women to develop treatment plans aligned with their symptoms, medical history, and long-term health goals.
As a Menopause Society Certified Practitioner and founder of Optimal Health and Vitality, I am committed to staying informed, participating in important conversations, and advocating for better menopause care.
Attending the FDA testosterone workshop and the Perimenopause Symposium this year strengthened that commitment.
Menopause is a natural biological transition, but suffering through debilitating symptoms should never be considered inevitable.
As we celebrate World Menopause Day 2026, I hope more women feel empowered to ask questions, seek knowledgeable healthcare professionals, and advocate for the care they deserve.
The conversation is changing. The science is advancing. And the future of menopause care is looking brighter.
Ready to Take Control of Your Menopause Journey?
If you are experiencing symptoms of perimenopause or menopause and are looking for individualized, evidence-based care, Optimal Health and Vitality is here to help.
Comments